Jacobs Levy Equity Management
KYTX icon

Jacobs Levy Equity Management’s Kyverna Therapeutics KYTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$143K Sell
16,599
-91,935
-85% -$766K ﹤0.01% 933
2025
Q4 		$1.02M Sell
108,534
-39,178
-27% -$291K ﹤0.01% 679
2025
Q3 		$886K Buy
+147,712
New +$591K ﹤0.01% 740
2025
Q1 		– Sell
-461,959
Closed -$1.73M – 1215
2024
Q4 		$1.73M Buy
461,959
+442,090
+2,225% +$2.12M 0.01% 623
2024
Q3 		$97.2K Buy
+19,869
New +$153K ﹤0.01% 934

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Jacobs Levy Equity Management's KYTX Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Kyverna Therapeutics (KYTX) stake by 85% in Q1 2026, selling an estimated $766K and leaving 16,599 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #933.

Jacobs Levy Equity Management first reported a position in KYTX in Q3 2024 and has held it in 5 quarters since. The position peaked at $1.73M in Q4 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Jacobs Levy Equity Management held 16,599 shares of Kyverna Therapeutics worth $143K as of Q1 2026.
  • Jacobs Levy Equity Management sold 91,935 Kyverna Therapeutics shares in Q1 2026, an estimated $766K.
  • Kyverna Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #933 holding.
  • Jacobs Levy Equity Management first reported a position in Kyverna Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Jacobs Levy Equity Management's Kyverna Therapeutics position peaked at $1.73M in Q4 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.